R&D Trends

Idera, GSK to collaborate on renal disease

Wednesday, November 25, 2015

Idera Pharmaceuticals, a Cambridge, Mass.-based clinical-stage biopharmaceutical company developing toll-like receptors and RNA therapeutics for patients with cancer and rare diseases, has entered into an exclusive worldwide collaboration and license agreement with GlaxoSmithKline to research, develop and commercialize selected molecules from Idera’s third-generation antisense platform for the treatment of selected targets in renal disease.

[Read More]

LSP, BMS team on European life sciences

Tuesday, November 24, 2015

Specialist healthcare investment firm LSP, also known as Life Sciences Partners, has formed a strategic collaboration with Bristol-Myers Squibb (BMS) in which the companies will work together to identify European breakthrough technologies and products in immuno-oncology and other areas of unmet medical need.

[Read More]

Kadmon, Jinghua collaborate in China

Monday, November 23, 2015

Kadmon has announced a new collaboration and license agreement with China’s Jinghua Pharmaceutical to discover, develop and commercialize Kadmon’s fully human anti-VEGFR2 and anti-PD-L1 monoclonal antibodies exclusively for Greater China. Kadmon also has licensed to Jinghua its technology and know-how to discover fully human monoclonal antibodies to develop further products for commercialization in the Chinese market.

[Read More]

Study: Global medicine spending to rise 30% by 2018

Wednesday, November 18, 2015

More specialty drug innovation, greater patient access to medicines and reduced impact from patent expiries will be the primary drivers of an increase in global medicine spending of up to 30% by 2018. The increase in annual spending will spike this year when absolute growth will be about $70 billion, up from $44 billion in 2013 and $26 billion in 2012, according to new research released by the IMS Institute for Healthcare Informatics.

[Read More]

Array, Pierre Fabre collaborate on oncology

Monday, November 16, 2015

Array BioPharma and Pierre Fabre are collaborating to globally develop and commercialize Array’s late-stage novel oncology products binimetinib and encorafenib. Binimetinib, a MEK inhibitor, and encorafenib, a BRAF inhibitor, currently are advancing in three global phase III trials for melanoma and ovarian cancer. Top-line results from NEMO, a phase III study of binimetinib in patients with NRAS-mutant melanoma, are anticipated before the end of 2015.

[Read More]